Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Oncotarget|July 26, 2018
Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, et al.
Scientific Reports|August 6, 2025
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumabToshihiko Matsumoto, Tatsuki Ikoma, Chinatsu Makiyama, et al.
Cancer Chemotherapy and Pharmacology|December 13, 2016
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104)Hironaga Satake, Masaaki Iwatsuki, Yoshikazu Uenosono, et al.
Annals of Surgery|October 20, 2018
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology GroupShogo Kobayashi, Hiroaki Nagano, Akira Tomokuni, et al.
Oncotarget|May 4, 2018
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2016
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinomaHironaga Satake, Makoto Tahara, Satoshi Mochizuki, et al.
International Journal of Clinical Oncology|May 16, 2020
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)Masahito Kotaka, Shigeyoshi Iwamoto, Hironaga Satake, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2019
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501BSatoshi Yuki, Katsunori Shinozaki, Tomomi Kashiwada, et al.
Japanese Journal of Clinical Oncology|December 19, 2022
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062Hironaga Satake, Keun-Wook Lee, Hyun Cheol Chung, et al.
Cancer Chemotherapy and Pharmacology|September 23, 2020
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathyMasahito Kotaka, Yoji Saito, Takeshi Kato, et al.
Pageof 12